In an effort to speed up the drug discovery process for multi-drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis, UCSD's Philip Bourne led work that used a proteomic, computational approach to identify cross-reactivity between different drug target families. The team showed that entacapone and tolcapone, two drugs used to treat Parkinson's disease, can also help treat MDR and XDR tuberculosis. The work appears in PLoS Computational Biology this week.